FAVIPIRAVIR INDUCED GENERAL MACULOPAPULER RASH IN PEDIATRIC COVID-19 CASE


Yüce M., KARA Y., KIZIL M. C., KILIÇ Ö., ŞAHİN S., DİNLEYİCİ E. Ç.

The 12th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), Yunanistan, 22 Şubat 2022, cilt.1, sa.153, ss.153-247

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Cilt numarası: 1
  • Basıldığı Ülke: Yunanistan
  • Sayfa Sayıları: ss.153-247
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background: COVID-19 has many findings apart from respiratory system symptoms such as fever, cough, and dyspnea. Skin manifestations are among the rarer symptoms of COVID-19. It has been reported to cause skin lesions such as maculopapular and urticaria. Here, a pediatric COVID-19 case presenting with a diffuse maculopapular rash after using favipiravir

Case: A 16-year-old boy presented with maculopapular rash. From history, COVID-PCR was positive four days ago and used favipiravir as a treatment. After favipiravir using, diffuse maculopapüler rash has occurred. On physical examination, there were a general maculopapular rash on the chest, back, and legs. In laboratory tests: hemoglobin 9.6 g/dL, leukocytes 13.500/mm3 (neutrophil 10.820/mm3, lymphocyte 1350/mm3), platelet 41.000/mm3, C-reactive protein 217 mg/L (0-5). No previous history of allergic rash, use of drugs other than favipiravir, and lack of different food intake, it was thought that the existing rashes could be skin findings of COVID-19 or due to favipiravir. Patient did not have cough and respiratory distress , favipiravir treatment was discontinued and oral antihistamine treatment was started. On the 3rd day of follow-up, the complaint of rash regressed. Oral antihistamine treatment was discontinued and it was recommended to continue home isolation.

Conclusions: During the pandemic period, the contact history of all patients should be questioned, as COVID-19 may cause atypical findings; It should not be forgotten that in the presence of maculopapular, urticarial, vesicular rash, there may be skin findings related to COVID-19.The side-effect profile of drugs used in the treatment of COVID-19 should be known and followed closely.